The U.S. FDA ordered Novartis and Fujisawa Healthcare to carry "black box" warnings on the labels of two eczema creams, saying the creams can be absorbed into the body where they can cause cancer and should be prescribed as drugs of last resort. The agency also warned babies should not be treated with Novartis' Elidel and Fujisawa's Protopic, after a trial found a link between an increased risk of upper respiratory infections and use of the cream.

Full Story:

Related Summaries